Markus A. Riederer, Ph.D, Head DD Biologhy, at Idorsia Pharmaceuticals Ltd. Switzerland.
After completion of my doctoral thesis at the University of Basel, Switzerland, I continued my scientific education with a postdoctoral fellowship at Stanford University, School of Medicine, Stanford, CA, USA.
My career in drug discovery started in the Thrombosis Group at Hoffmann-La Roche, Switzerland with research on the fibrinogen receptor GP IIb-IIIa. Subsequently, as a Project Leader of the “Novel Oral Anticoagulant Project”, my focus was shifted to the TF/F.VIIa coagulation pathway. In my new role as group leader in Actelion Pharmaceuticals Ltd. leading me into my current position, my scientific focus shifted back to platelet biology with the goal to discover and profile a novel P2Y12 antagonist.